The Filing Desk

Aurinia Pharmaceuticals vs Rigel Pharmaceuticals

Aurinia Pharmaceuticals AUPH · Rigel Pharmaceuticals RIGL · Pharmaceuticals

Rigel Pharmaceuticals reported revenue of $294 million in fiscal 2025, about the same as Aurinia Pharmaceuticals' $283 million in fiscal 2025. Aurinia Pharmaceuticals' revenue grew 20.4% in its latest year, and Rigel Pharmaceuticals' grew 64.2%. Aurinia Pharmaceuticals had an operating margin of 37.1%, against 42.6% at Rigel Pharmaceuticals.

Side by side

Aurinia PharmaceuticalsRigel Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$283M$294M
Revenue growth20.4%64.2%
Revenue growth a year, last 5 years41.4%22.1%
Gross margin88.5%93.3%
Operating margin37.1%42.6%
Net margin101.5%124.7%
Free cash flow$135M—
Free cash flow margin47.8%—
Return on capital—91.3%
Net debt to EBITDA—−0.8x
Dividends and buybacks$98M$0M
Change in diluted share count−5.1%6.5%
Last close$15.73$44.46
P/E at the last close6.9×2.8×
Insider trades, last 12 monthsbought $25.1 million, sold $546,373—
Piotroski F-score—7 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aurinia PharmaceuticalsRigel Pharmaceuticals
Operating margin
Percent of revenue
Aurinia PharmaceuticalsRigel Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aurinia PharmaceuticalsRigel Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aurinia Pharmaceuticals and Rigel Pharmaceuticals pages.